Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexamethasone/CRH and alprazolam testing for pseudo-Cushing's syndrome diagnosis
jRCT1021210011Recruiting
- Start
- Apr 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of dexamethasone, corticotrophin-releasing hormone and alprazolam in Nonneoplastic Hypercortisolism (NNH) and Cushing's syndrome. Primary endpoint: Primary: Hormone responses after alprazolam and dexamethasone/CRH testing. Started Apr 2022; status: recruiting.
02
Drugs
dexamethasonecorticotrophin-releasing hormonealprazolam
03
Conditions
Nonneoplastic Hypercortisolism (NNH)Cushing's syndrome
Beyond the preview
Go deeper on jRCT1021210011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1021210011.